CRISPR Therapeutics AG (CRSP) Non-Current Debt (2026)

CRISPR Therapeutics AG (CRSP) reported Non-Current Debt of $585.5 million for Q1 2026.

CRISPR Therapeutics AG (CRSP) Non-Current Debt (2026) Analysis & Trends

CRISPR Therapeutics AG (CRSP) has 1 years of Non-Current Debt data on file, last reported at $585.5 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 105.94 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 842.92 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 CRISPR Therapeutics AG 4.57 Bn 2.12 Bn - 585.47 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 585.47 Mn